CN107722074B - Calcium-containing compound separated from vinegar egg liquid and application thereof - Google Patents
Calcium-containing compound separated from vinegar egg liquid and application thereof Download PDFInfo
- Publication number
- CN107722074B CN107722074B CN201710877739.4A CN201710877739A CN107722074B CN 107722074 B CN107722074 B CN 107722074B CN 201710877739 A CN201710877739 A CN 201710877739A CN 107722074 B CN107722074 B CN 107722074B
- Authority
- CN
- China
- Prior art keywords
- compound
- calcium
- vinegar
- egg liquid
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 239000011575 calcium Substances 0.000 title abstract description 12
- 239000007788 liquid Substances 0.000 title abstract description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title abstract description 11
- 229910052791 calcium Inorganic materials 0.000 title abstract description 11
- 239000000052 vinegar Substances 0.000 title abstract description 11
- 235000021419 vinegar Nutrition 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 12
- 229960001436 calcium saccharate Drugs 0.000 abstract description 11
- 230000036772 blood pressure Effects 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 9
- 239000008103 glucose Substances 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- -1 calcium saccharate compound Chemical class 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 8
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 8
- UGZVNIRNPPEDHM-SBBOJQDXSA-L calcium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Ca+2].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UGZVNIRNPPEDHM-SBBOJQDXSA-L 0.000 description 8
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 239000001639 calcium acetate Substances 0.000 description 6
- 229960005147 calcium acetate Drugs 0.000 description 6
- 235000011092 calcium acetate Nutrition 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 241000209051 Saccharum Species 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002584 ketoses Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 241000284466 Antarctothoa delta Species 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a calcium-containing compound separated from vinegar egg liquid and application thereof, belonging to the technical field of food and medicine. The invention extracts the compound with the functions of reducing blood pressure and blood sugar from the vinegar-soaked egg solution, and verifies the effect of the compound on the functions of reducing blood pressure and blood sugar. The result shows that the IC for inhibiting the ACE is 30min after the calcium saccharate compound with the concentration of 50-200 mu g/mL is added50The value is 11.7-34 mu g/mL; according to the results of animal experiments, the fasting blood glucose level of diabetic mice was decreased by 27.67% 2 weeks after administration of the compound of the present invention.
Description
Technical Field
The invention relates to a calcium-containing compound separated from vinegar egg liquid and application thereof, belonging to the technical field of food and medicine.
Background
Vinegar egg liquid is a traditional food therapy product in China, and is recorded in Shang Han dynasty Zhang Zhongjing in Shang Han dynasty. The vinegar egg liquid has effects of softening blood vessel, lowering blood pressure, reducing cholesterol, and reducing blood sugar. It can be used for preventing and treating 70 kinds of diseases such as cardiovascular and cerebrovascular diseases, liver and kidney diseases, etc. However, the specific functional components are not clear, and the mechanism of the effect cannot be clarified. The relevant documents report that the vinegar egg liquid contains a large amount of calcium and exists in the form of calcium acetate, but no report is found that the calcium acetate compound with the above effects is separated from the vinegar egg liquid.
Therefore, the separation and obtaining of the effective components in the vinegar-soaked eggs have very important effects on the prevention of diseases such as cardiovascular and cerebrovascular diseases, liver and kidney diseases and the like. .
Disclosure of Invention
According to the invention, through the component research on the vinegar-pickled egg liquid, the vinegar-pickled egg contains calcium acetate substances, but the substances do not exist in a free form, but exist in a form of combining calcium acetate and oligosaccharide, so that the functional compound is extracted and the applications possibly related to the functional compound are provided.
A first object of the present invention is to provide a compound having the structural formula:wherein R is
In one embodiment of the invention, the compound is white amorphous powder, and the melting point is 187-189 ℃.
In one embodiment of the invention, the nmr data for the compound is as shown in the following table:
from1H-NMR showed δ 5.11(1H, d, J ═ 3.6), 4.51(1H, d, J ═ 7.6), these two H signals should be terminal signals for sugars, 3.0 to 4.1 for H signals on sugars, 1.79(3H, s), for methyl signals. In that13C-NMR 20 carbon signals in total, delta 181.7 is a carbonyl carbon signal indicating that the compound contains a carboxyl group, delta 98.0, 95.8, 92.0 has three carbon signals, which should be terminal carbon signals of the sugar, indicating that the compound has three sugar residues, and1only two terminal H signals are visible in H-NMR, and from the 135dept spectrum, a quaternary carbon (. delta.98.0) is indicated, which gives compounds containing a ketose, the 135dept spectrum showing that. delta.63.8, 63.3, 62.6, 60.7 are CH2A signal. From the chemical shift values of the sugars and the 135dept information it was determined that the compounds contained two glucose residues and one fructose group. δ 23.3 is the methyl signal, which indicates that the carbonyl group of δ 181.7 should form an acetate group with the methyl group.
The second purpose of the invention is to provide the application of the compound in preparing the medicine for treating hypertension, hyperlipemia, cardiovascular and cerebrovascular diseases, or liver and kidney diseases.
The third purpose of the invention is to provide the application of the compound in preparing health products with the functions of softening blood vessels, reducing blood pressure, reducing cholesterol or reducing blood sugar.
The fourth purpose of the invention is to provide the application of the compound in the non-medical application in the food field.
The compound of the invention is prepared by the following steps:
(1) concentrating the vinegar-soaked egg solution to one fifth volume, adding four times of the concentrated 95% (v/v, mL/mL) ethanol solution while stirring, standing for more than 4 hours, and filtering to obtain precipitate;
(2) dissolving the precipitate obtained in the step (1) with a proper amount of water, loading the precipitate onto an MCI chromatographic column, eluting with deionized water with twice the volume of the column, eluting with an ethanol solution with a volume fraction of 10% with three times the volume of the column, collecting the eluent, and concentrating the eluent to one fifth of the volume;
(3) and (3) separating the eluate concentrated in the step (2) by using an ODS-AQ column, eluting with deionized water, eluting with ethanol with the volume fraction of 6%, collecting the ethanol eluate, continuously separating the ethanol eluate on the ODS-AQ column, and repeating the step (3) for 2-3 times.
Has the advantages that: the invention extracts the compound with the functions of reducing blood pressure and blood sugar from the vinegar-soaked egg solution, and verifies the effect of the compound on the functions of reducing blood pressure and blood sugar. The results show that IC is obtained 30min after adding 50-200. mu.g/mL sugar calcium compound50The value is 11.7-34 mu g/mL; according to the results of animal experiments, after the compound of the invention is administrated for 2 weeks, the fasting blood glucose value of the diabetic mice is reduced by 27.67 percent,
drawings
FIG. 1 is an HPLC spectrum of compound calcium saccharate;
FIG. 2 is a mass spectrum of LC-MS of compound calcium saccharate;
FIG. 3 shows the compound of sugar calcium13C-NMR spectrum.
Detailed Description
EXAMPLE 1 extraction of sugar calcium Compound
(1) Preparing vinegar egg liquid: adding 15kg of 9-degree vinegar into 10kg of eggs, soaking for 24h, stirring to break egg skins, soaking for 24h, and filtering to obtain filtrate to obtain vinegar-egg liquid.
(2) Concentrating 10L vinegar egg liquid to 2L volume, adding 8L 95% ethanol under stirring, standing for more than 4 hr, and filtering to obtain precipitate.
(3) Dissolving the precipitate with 0.5L water, filtering to remove impurities, separating the supernatant with MCI column (5 × 150cm), eluting with 6L deionized water, eluting with 9L 10% ethanol, collecting 10% ethanol eluate, and concentrating to 1.8L volume.
(4) And (3) reversely multiplexing the 10% ethanol elution concentrated solution for ODS-AQ column separation, eluting with deionized water, eluting with 6% ethanol, repeatedly separating with the ODS-AQ column for 2-3 times, and detecting by a TLC method until a single point is obtained, namely the single compound. The obtained eluate was dried to obtain 11.7g of white amorphous powder of calcium saccharate, which was named as calcium saccharate. .
EXAMPLE 2 identification of Saccharum compounds
The compound obtained in example 1 was identified by HPLC \ HPLC-MS and nuclear magnetic resonance, respectively.
(1)HPLC
Adopting ODSC18 chromatographic column and methanol: water (6: 94) mobile phase, with flow rate of 0.3mL/min, and detecting wavelength of 228nm chromatogram shown in FIG. 1; the chromatographic peak at a retention time of 1.56min was the compound obtained in step 1.
(2)HPLC-MS
The mass spectrum using ESI + mode at 1800v is shown in FIG. 2.
(3) Nuclear magnetic resonance with D2O as solvent, tetramethylsilane as internal standard, Bruck 500MZNMR measurement was carried out.
TABLE 1 NMR results
From1H-NMR showed δ 5.11(1H, d, J ═ 3.6), 4.51(1H, d, J ═ 7.6), these two H signals should be terminal signals for sugars, 3.0 to 4.1 for H signals on sugars, 1.79(3H, s), for methyl signals. In that13C-NMR has a total of 20 carbon signals, a.delta.181.7 ofCarbonyl carbon signal, indicating that the compound contains carboxyl groups, delta 98.0, 95.8, 92.0 has three carbon signals, which should be terminal carbon signals of sugars, indicating that the compound has three sugar residues, and1only two terminal H signals are visible in H-NMR, and from the 135dept spectrum, a quaternary carbon (. delta.98.0) is indicated, which gives compounds containing a ketose, the 135dept spectrum showing that. delta.63.8, 63.3, 62.6, 60.7 are CH2A signal. From the chemical shift values of the sugars and the 135dept information it was determined that the compounds contained two glucose residues and one fructose group. δ 23.3 is the methyl signal, which indicates that the carbonyl group of δ 181.7 should form an acetate group with the methyl group.
From the mass fragment analysis, the m/z 130 fragment is CH3COO-Ca-O-CH2-H, i.e. a Ca bond to acetic acid and a bond to a hydroxyl group on the sugar. The compound contains 3 fragments with m/z of 130, indicating that 3 calcium acetate are attached to different sites of the sugar, from this point on13The abundance of the carboxyl and methyl signals in the C-NMR spectrum can be seen. In nuclear magnetic resonance experiments, calcium has a shielding effect, the connected carbon moves to a high field, and the carbon 3-position chemical shift value of the sugar is relatively small, so that the calcium acetate is determined to be connected with the C3 site of the sugar.
EXAMPLE 3 use of Glycalcium Compounds for lowering blood pressure
The invention utilizes the inhibition effect on angiotensin-converting enzyme (ACE) to test the effect of sugar calcium in lowering blood pressure. Preparing 100 mU L of 50, 100 and 200 mU g/mL calcium saccharate solution, respectively adding 40 mU L of 25mU U of ACE enzyme solution, preserving the temperature at 37 ℃ for 30 minutes, adding 200 mU L of 1mol/L hydrochloric acid, and measuring the absorbance at the wavelength of 228 nm. The deionized water was used as a blank, and the difference ratio between different concentrations of calcium saccharate and the blank was the inhibition ratio, and the results are shown in table 2.
TABLE 2 inhibitory Effect of Saccharum calcium on ACE
ACE is angiotensin converting enzyme, which acts through the renin-angiotensin system and kallikrein-kinin system to cause blood pressure elevation, and it can inhibit ACE activity to lower blood pressure. It can be seen from table 2 that calcium saccharate has a better ACE inhibitory activity, indicating that calcium saccharate has a blood pressure lowering effect.
EXAMPLE 4 use of Glycalcium compounds for lowering blood glucose
The invention utilizes the alloxan diabetes mouse to detect the hypoglycemic effect of the calcium saccharate,
taking ICR male mice, and raising the mice in cages in animal laboratories (20 +/-2) DEG C for 12 hours each in light and shade, wherein the experimental animals can freely drink and eat water. Feeding normally for 3 days, after fasting for 18h, injecting alloxan solution at the dose of 60mg/kg, measuring postprandial blood sugar for 72h, and using mice with blood sugar value > 20.0mmol/L as hyperglycemia model.
Animals were randomly divided into 5 groups according to blood glucose level, and each group contained 9 animals, which were a model control group, a positive control group (metformin 240mg/kg), and a calcium-sugar group. Each administration group is administered by intragastric administration at a volume of 10ml/kg once a day with an administration amount of 500 mg/kg-1The model control group was given an equal amount of distilled water. After 2 weeks of continuous administration, postprandial blood glucose and post-administration fasting blood glucose were measured.
TABLE 3 Effect of calcium saccharate on blood glucose in diabetic mice
Note: p <0.05, P <0.01
From Table 3, the sugar calcium content was 500 mg/kg-1After 2 weeks of administration, the fasting blood glucose value of the diabetic mice was decreased by 27.67% and showed a significant difference (p < 0.05) compared to the model control group, thus indicating that the calcium gluconate had the effect of decreasing fasting blood glucose in the diabetic mice.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (3)
2. A composition comprising a compound of claim 1.
3. The use of a compound according to claim 1 for the manufacture of a medicament for the treatment of hypertension, hyperlipidemia, cardiovascular and cerebrovascular diseases, or liver and kidney diseases.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710877739.4A CN107722074B (en) | 2017-09-26 | 2017-09-26 | Calcium-containing compound separated from vinegar egg liquid and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710877739.4A CN107722074B (en) | 2017-09-26 | 2017-09-26 | Calcium-containing compound separated from vinegar egg liquid and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107722074A CN107722074A (en) | 2018-02-23 |
CN107722074B true CN107722074B (en) | 2020-01-24 |
Family
ID=61206887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710877739.4A Active CN107722074B (en) | 2017-09-26 | 2017-09-26 | Calcium-containing compound separated from vinegar egg liquid and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107722074B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008290995A (en) * | 2007-05-28 | 2008-12-04 | Otaka Koso Kk | New oligosaccharide and its manufacturing method |
CN103588827A (en) * | 2012-08-15 | 2014-02-19 | 天津天士力现代中药资源有限公司 | Separation and purification method for oligomeric trisaccharide in compound red sage root extract |
-
2017
- 2017-09-26 CN CN201710877739.4A patent/CN107722074B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008290995A (en) * | 2007-05-28 | 2008-12-04 | Otaka Koso Kk | New oligosaccharide and its manufacturing method |
CN103588827A (en) * | 2012-08-15 | 2014-02-19 | 天津天士力现代中药资源有限公司 | Separation and purification method for oligomeric trisaccharide in compound red sage root extract |
Non-Patent Citations (3)
Title |
---|
Structural Analysis of Two Trisaccharides Isolated from Fermented Beverage of Plant Extract.;Naoki Kawazoe, et al.,;《Open Glycoscience》;20081231;第1卷;第25-30页. * |
分离纯化醋蛋水解物制备降血压肽的研究.;陈黎斌等,;《食品科技》;20111231;第36卷(第4期);第78-80、88页. * |
醋蛋液的成分及保健功效研究进展.;王学英等,;《中国调味品》;20131231;第38卷(第5期);第7-11页. * |
Also Published As
Publication number | Publication date |
---|---|
CN107722074A (en) | 2018-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2246047B1 (en) | Use of lanostane derivatives in treating cachexia | |
EP2668954A1 (en) | Extraction method, total saponin and use of ilex kudingcha c.j.tseng leaves | |
CN108659068A (en) | A kind of isolation and purification method of Cyanidin -3-O- rutinosides and its application | |
US11384109B2 (en) | Method for separating phenolic acid glucoside compounds from Diaphragma juglandis Fructu | |
Rodríguez-Sánchez et al. | New methodologies for the extraction and fractionation of bioactive carbohydrates from mulberry (Morus alba) leaves | |
EP3412679A1 (en) | Baicalin magnesium, preparation method thereof and application of same | |
CN101130561A (en) | Method for producing salidroside and injection containing the same | |
Ren et al. | Structural characterization and tartary buckwheat polysaccharides alleviate insulin resistance by suppressing SOCS3-induced IRS1 protein degradation | |
JP2002267655A (en) | Plant of genus euonymus family salacia and/or method of judging quality in extract from the plant | |
CN103860546A (en) | Application of abietane derivative in medicament for diseases caused by inflammatory mediators | |
CN115703740B (en) | Preparation method of bulleyaconitine A | |
CN107722074B (en) | Calcium-containing compound separated from vinegar egg liquid and application thereof | |
Lü et al. | Trapa natans pericarp extract ameliorates hyperglycemia and hyperlipidemia in type 2 diabetic mice | |
Sharma et al. | Dereplication based strategy for rapid identification and isolation of a novel anti-inflammatory flavonoid by LCMS/MS from Colebrookea oppositifolia | |
CN108409805A (en) | A kind of isolation and purification method of delphinidin -3-O- galactosides and its application | |
CA2502703A1 (en) | A natural compound for prevention and treatment of diabetes, process for preparing the same, and pharmaceutical use thereof | |
CN110237064B (en) | Application of dicaffeoylquinic acid in preparing medicine for treating gout | |
CN108822168B (en) | Separation and purification method of malvidin-3-O-galactoside and application thereof | |
CN107383122B (en) | Method for extracting α -glucosidase inhibitor from carambola root | |
CN106822095B (en) | Medicine for preventing and treating fatty liver and obesity and application thereof in pharmacy | |
KR20070073663A (en) | Preparation method for the extract from maca and the composition containing the same | |
CN111153883B (en) | Mixed-element terpenoid Verruculide B4 and preparation method and application thereof | |
CN111773257B (en) | Hippophae rhamnoides extract and its use | |
CN114766671A (en) | Preparation method of black jerusalem artichoke polyphenol with activity of inhibiting colon cancer cell proliferation | |
CN110898116B (en) | Paederia scandens extract and separation preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |